Week 26 - Jun 23-29, 2025

🚨 Biotech & Pharma Industry Highlights – Latest Announcements 🚨 Here are some recent developments shaping innovation across neuroscience, oncology, mental health, and regenerative medicine:🔬 New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA Biogen presents new clinical data showing improved motor outcomes with a higher dose of nusinersen in SMA patients.💊 PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares C$600,000 raised to support further development of psilocybin-based mental health therapies.🧬 FDA Grants RMAT Designation for enGene’s Detalimogene A significant milestone for enGene’s bladder cancer gene therapy candidate, enabling faster review and development.🧠 Biogen to Advance Investigational SMA Asset to Registrational Studies Positive Phase 1 results prompt progression of once-yearly ASO therapy for SMA to late-stage trials.🧪 Enveric Biosciences Announces Data on EB-003 Lead compound targets serotonin receptors with the potential to treat depression and neurological conditions without hallucinogenic effects.🌱 Triple Hair Group Signs Licensing Agreement for Brazil with Aché Strategic expansion into Brazil's $6B hair care market with exclusive rights granted to Aché.📈 Quantum BioPharma Announces Private Placement $600M private placement to fund innovative treatments for neurodegenerative disorders through Lucid Psycheceuticals Inc.🧫 Kane Biotech Converts Insider Loan and Reports AGM Results Governance updates and financial restructuring to support ongoing work in wound care and biofilm disruption.💡 Follow the BioTech Weekly newsletter for more updates on biotech breakthroughs, regulatory milestones, and investment trends in life sciences. #Biotech #Pharma #LifeSciences #ClinicalTrials #DrugDevelopment #HealthcareInnovation #SMA #CancerResearch #MentalHealthDisclaimer: This podcast includes content generated with the help of large language models (LLM). Although care has been taken to ensure accuracy, LLMs can sometimes produce incorrect or misleading information. Listeners are advised to independently verify any details, provide feedback, and reach out.

There are no comments yet.

Please log in to write the first comment.